文献速递糖尿病

钠-葡萄糖协同转运蛋白2抑制剂用于COVID-19住院患者:随机试验的前瞻性荟萃分析

Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials.
PubMed 文献 · Lancet Diabetes Endocrinol · 2024-09-06

该前瞻性荟萃分析纳入3项随机对照试验共6096例COVID-19住院成人,比较口服SGLT2抑制剂与常规治疗或安慰剂。28天全因死亡在SGLT2抑制剂组351例、对照组382例,汇总OR 0.93(95%CI 0.79-1.08;P=0.33;异质性I²=0%),无明确获益证据;酮酸中毒在SGLT2抑制剂组7例、对照组2例。

要点

  • 在COVID-19住院成人中,SGLT2抑制剂组28天死亡351例,常规治疗或安慰剂组382例,汇总OR 0.93(95%CI 0.79-1.08;P=0.33)。
  • 试验间异质性I²=0%,偏倚风险评估为低。
  • 酮酸中毒在SGLT2抑制剂组7例、常规治疗或安慰剂组2例。

核心结论

  • 尽管SGLT2抑制剂给药是安全的,但与常规治疗或安慰剂相比,未发现明确证据表明加用SGLT2抑制剂治疗可改善COVID-19住院患者的结局。
  • 这些数据不支持将SGLT2抑制剂作为COVID-19住院成人的标准治疗。

研究设计与样本

  • 前瞻性荟萃分析,纳入评估口服SGLT2抑制剂对比常规治疗或安慰剂对28天全因死亡率(主要结局)影响的合格随机对照试验。
  • 3项合格试验随机分配6096例参与者,其中SGLT2抑制剂组3025例、常规治疗或安慰剂组3071例。
  • 2381例(39%)为女性,1547例(25%)随机分组时患有2型糖尿病。
  • 通过2022年11月1日至2023年1月31日对ClinicalTrials.gov、EudraCT和WHO ISRCTN注册库的系统检索识别试验,检索词为「random*」AND「COVID」AND每种SGLT2抑制剂,不限试验状态或语言。
  • 主要分析为比值比(OR)的逆方差加权荟萃分析;偏倚风险采用Cochrane偏倚风险工具评估;研究注册于PROSPERO,CRD42023406442。

主要发现

  • 至28天,SGLT2抑制剂组死亡351例,常规治疗或安慰剂组死亡382例(汇总OR 0.93 [95%CI 0.79-1.08];P=0.33,试验间不一致性I²=0%)。
  • 偏倚风险评估为低。
  • 酮酸中毒在SGLT2抑制剂组7例参与者中观察到,在常规治疗或安慰剂组2例患者中观察到。

关键数值与推荐

  • 主要结局为28天全因死亡率;主要安全性结局为28天内酮酸中毒。
  • 汇总OR 0.93(95%CI 0.79-1.08;P=0.33)对应的对象为SGLT2抑制剂组对比常规治疗或安慰剂组的28天全因死亡。
  • 酮酸中毒在SGLT2抑制剂组7例、常规治疗或安慰剂组2例。

临床怎么用

  • 作者认为这些数据不支持将SGLT2抑制剂作为COVID-19住院成人的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been proposed as a potential treatment for adults hospitalised with COVID-19, due to their potential anti-inflammatory and endothelial protective effects. Published evidence from randomised control trials (RCTs) does not provide evidence of benefit. We aimed to estimate the effect of oral administration of SGLT2 inhibitors compared with usual care or placebo in adults hospitalised with COVID-19. METHODS: Eligible RCTs that estimated the effect of oral administration of SGLT2 inhibitors compared with usual care or placebo on 28-day all-cause mortality (primary outcome) were included in this prospective meta-analysis. The primary safety outcome was ketoacidosis by 28 days. Trials were identified through systematic searches of ClinicalTrials.gov, EudraCT, and the WHO ISRCTN registry between Nov 1, 2022 and Jan 31, 2023. The search terms were "random*" AND "COVID" AND each SGLT2i, not restricted by trial status or language. Individual searches were then combined. Prespecified summary outcome data, overall and within subgroups of interest, were provided by each trial. The primary analyses were inverse variance weighted meta-analysis of odds ratios (ORs). Risk of bias was assessed using the Cochrane Risk of Bias tool. This study was registered with PROSPERO, CRD42023406442. FINDINGS: Three eligible trials randomly assigned 6096 participants (3025 to the SGLT2 inhibitor group and 3071 to the usual care or placebo group). 2381 (39%) patients were women and 1547 (25%) had type 2 diabetes at randomisation. By 28 days, there were 351 deaths in the SGLT2 inhibitor group and 382 deaths in the usual care or placebo group (summary OR 0·93 [95% CI 0·79-1·08]; p=0·33, I2 for inconsistency across trials 0%). The risk of bias was assessed as being low. Ketoacidosis was observed in seven participants in the SGLT2 inhibitor group and two patients in the usual care or placebo group. INTERPRETATION: Although administration of SGLT2 inhibitor was safe, we found no clear evidence that adding SGLT2 inhibitor therapy improved outcomes in patients hospitalised with COVID-19 compared with usual care or placebo. These data do not support the use of SGLT2 inhibitors as standard treatment in adults hospitalised for COVID-19. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Vale C, Godolphin PJ, Fisher D, et al. Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2024. PMID: 39250923. doi:10.1016/S2213-8587(24)00219-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。